nach oben

Breast Cancer Research and Treatment

Erschienen in:

22.05.2019 | Letter to the Editor

What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

verfasst von: Roberta Maltoni, Sara Bravaccini

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …

de Nonneville A, Jauffret C, Gonçalves A et al (2019) Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05160-9 CrossRefPubMed

de Melo Gagliato D, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744CrossRef

Curigliano G, Burstein HJ, Winer EP et al (2017) De-escalating and escalating treatments for early-stage breast cancer the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol 28(8):1700–1712CrossRefPubMedPubMedCentral

Farolfi A, Scarpi E, Rocca A et al (2015) Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer 51(14):1874–1881CrossRefPubMed

Titel: What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
verfasst von: Roberta Maltoni
Sara Bravaccini
Publikationsdatum: 22.05.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05275-z

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Radiation oncology crossword: breast cancer

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

Breast cancer outcome prediction with tumour tissue images and machine learning

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

Sharing in care: engaging care partners in the care and communication of breast cancer patients

Employment trends in young women following a breast cancer diagnosis

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie